Impact BioMedical Net Income Over Time
| IBO Stock | USD 0.45 0.03 6.25% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Impact BioMedical Performance and Impact BioMedical Correlation. Will Biotechnology sector continue expanding? Could Impact diversify its offerings? Factors like these will boost the valuation of Impact BioMedical. Market participants price Impact higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Impact BioMedical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Impact BioMedical's market price often diverges from its book value, the accounting figure shown on Impact's balance sheet. Smart investors calculate Impact BioMedical's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Impact BioMedical's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Impact BioMedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Impact BioMedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Impact BioMedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Impact BioMedical and related stocks such as Neurosense Therapeutics, AIM ImmunoTech, and Brainstorm Cell Ther Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRSN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (2.8 M) | (4 M) | (12.3 M) | (10.1 M) | (10.2 M) | (9.2 M) | (9.6 M) |
| AIM | (1.8 M) | (9 M) | (17.4 M) | (16.2 M) | (17.4 M) | (15.2 M) | (7.5 M) | (8.3 M) | (9.8 M) | (9.4 M) | (14.4 M) | (19.1 M) | (19.4 M) | (29 M) | (17.3 M) | (15.6 M) | (16.4 M) |
| BCLI | (25.6 K) | (3.9 M) | (3.4 M) | (4.9 M) | (9.2 M) | (8.5 M) | (5 M) | (5 M) | (13.9 M) | (23.3 M) | (31.8 M) | (24.5 M) | (23.7 M) | (17.2 M) | 11.6 M | 10.5 M | 11 M |
| TCRT | (72.5 K) | (63.8 M) | (96.1 M) | (57.1 M) | (31.8 M) | (120.1 M) | (165.3 M) | (54.3 M) | (53.1 M) | (117.8 M) | (78.8 M) | (78.8 M) | (37.7 M) | (35.1 M) | (4.7 M) | (4.2 M) | (4.4 M) |
| MLEC | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (4.5 M) | (51.8 M) | (7.3 M) | (111.5 M) | (100.3 M) | (95.3 M) |
| CYCN | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (93.9 M) | (115.3 M) | (123 M) | (77.8 M) | (51.6 M) | (44.1 M) | (5.3 M) | (3.1 M) | (3.5 M) | (3.7 M) |
| QNRX | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | 15.3 M | 10.2 M | 15.3 M | (1.6 M) | (2.1 M) | (21.5 M) | (9.4 M) | (8.7 M) | (9 M) | (8.1 M) | (7.7 M) |
| ADIL | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (420.2 K) | (1.1 M) | (11.6 M) | (8.6 M) | (10.9 M) | (19.4 M) | (12.7 M) | (7 M) | (13.2 M) | (11.9 M) | (12.5 M) |
| XTLB | (12.7 M) | (1.2 M) | (1.4 M) | (2.5 M) | (2.5 M) | (4.3 M) | (2.5 M) | (781 K) | 3 M | (1.3 M) | (782 K) | 435 K | (1.3 M) | (1.8 K) | (1 M) | (1.2 M) | (1.2 M) |
| XBIO | (6.3 M) | (6.3 M) | (6.3 M) | (8.6 M) | (14.3 M) | (12.5 M) | (54.2 M) | (3.6 M) | (7.3 M) | (12.8 M) | (10.9 M) | (5.6 M) | (6.6 M) | (4.1 M) | (4 M) | (4.6 M) | (4.8 M) |
Impact BioMedical and related stocks such as Neurosense Therapeutics, AIM ImmunoTech, and Brainstorm Cell Ther Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Impact BioMedical financial statement analysis. It represents the amount of money remaining after all of Impact BioMedical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Impact BioMedical | IBO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1400 Broadfield Blvd, |
| Exchange | AMEX Exchange |
USD 0.45
Check out Impact BioMedical Performance and Impact BioMedical Correlation. To learn how to invest in Impact Stock, please use our How to Invest in Impact BioMedical guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Impact BioMedical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.